Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brazikumab in Moderately to Severely Active Ulcerative Colitis
NCT03616821Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Aug 2018
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 19
01
Overview
Phase 2, randomised, double-blind trial of brazikumab in ulcerative colitis (UC) (3 arms), sponsored by AstraZeneca. Primary endpoint: Clinical Remission at 10 weeks. Started Aug 2018; status: terminated.
02
Drugs
brazikumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03616821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03616821.